Méthodes pour traiter ou prévenir un cancer chez un patient porteur d'un variant kras et pour diagnostiquer un risque de développer des tumeurs du sein primaires multiples

Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors

  • Inventors: WEIDHAAS, JOANNE
  • Assignees: Miradx
  • Publication Date: October 13, 2016
  • Publication Number: WO-2016094854-A3

Abstract

The invention relates to methods for preventing cancer in a KRAS -variant subject which include administering to the KRAS -variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS -variant subject, which include gradually decreasing estrogen exposure in the KRAS -variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.
La présente invention concerne des méthodes de prévention du cancer chez un sujet porteur d'un variant de KRAS , qui comprennent l'administration audit sujet porteur d'un variant de KRAS d'une quantité d'œstrogènes efficace pour réduire le risque de développer un cancer. Dans un autre aspect, l'invention concerne en outre des méthodes de traitement du cancer chez un sujet porteur d'un variant de KRAS , qui incluent la diminution progressive de l'exposition aux œstrogènes chez le sujet atteint d'un variant de KRAS pour réduire le risque de croissance agressif de la tumeur. Dans un autre aspect, l'invention concerne un procédé de prédiction d'un risque accru de développer un second cancer du sein indépendant chez un sujet. Le procédé peut comprendre la détection d'un polymorphisme d'un nucléotide unique (SNP) à la position 4 du site complémentaire 6 let -7 de KRAS dans un échantillon de patient, la présence dudit SNP indiquant un risque accru de développer un second cancer indépendant chez ledit sujet.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (4)

    Publication numberPublication dateAssigneeTitle
    US-2005031695-A1February 10, 2005Ascend Therapeutics, Inc.Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
    US-2010021529-A1January 28, 2010Matthias Schafer, Gerard Nahum, Vladimir Hanes, Jan-Peter IngwersenStep-down estrogen regimen for women receiving estrogen therapy
    US-2012028254-A1February 02, 2012Weidhaas Joanne BSNP Marker of Breast and Ovarian Cancer Risk
    US-2014024590-A1January 23, 2014Yale UniversityKRAS-Variant And Endometriosis

NO-Patent Citations (5)

    Title
    LEE ET AL.: "The KRAS-variant and miRNA Expression In RTOG Endometrial Cancer Clinical Trials 9708 And 9905.", PLOS ONE., vol. 9, no. 4, April 2014 (2014-04-01), pages 1 - 8, XP055322113
    MARSA, L .: "The Little-Known Genetic Mutation Behind Many Aggressive Cancers.", DISCOVER MAGAZINE., 30 October 2014 (2014-10-30), pages 1 - 9, XP055322125
    MUNGENAST ET AL.: "Estrogen Biosynthesis And Action In Ovarian Cancer.", FRONTIERS IN ENDOCRINOLOGY., vol. 5, no. 192, 12 November 2014 (2014-11-12), pages 1 - 12, XP055322119
    NESS ET AL.: "Risk Of Ovarian Cancer In Relation To Estrogen And Progestin Dose And Use Characteristics Of Oral Contraceptives.", AMERICAN JOURNAL OF EPIDEMIOLOGY., vol. 152, no. 3, 2000, pages 233 - 241, XP055322111
    WEIDHAAS, J.: "Our Next Study: How Does Breast Cancer Treatment Impact Second Brest Cancer Risk?", MIRAKIND BLOG., 10 July 2014 (2014-07-10), pages 1 - 3, XP055322115, Retrieved from the Internet

Cited By (0)

    Publication numberPublication dateAssigneeTitle